RxDoctor Payments Data

Earline Little

Adult Health · Mc Coll, SCNPI 1487073219

Payments from drug & device makers

$2,021in general payments, 2019–2025

Across 120 payments — averaging $16.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$618
  • AbbVie$593
  • Bayer$109
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$103
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$92
  • Xeris Pharmaceuticals, Inc.$74
  • plus $432 from 12 others

What the payments were for

  • Food & beverage$2,021100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,021 in reported general payments places this provider in the 65th percentile of 292 adult health providers in South Carolina.

See all adult health providers in South Carolina

Medicare billing

Part B allowed, 2024
$2,303
Medicare patients
54
Services billed
260

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin92$113,815
OzempicSemaglutide80$96,153
RybelsusSemaglutide40$57,167
LinzessLinaclotide79$52,659
FarxigaDapagliflozin Propanediol43$50,733
EliquisApixaban76$49,242
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$35,605
MounjaroTirzepatide37$34,598
JanuviaSitagliptin Phosphate27$23,655
XareltoRivaroxaban23$21,175
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr29$15,200
GemtesaVibegron11$9,361
Breo ElliptaFluticasone/Vilanterol19$7,683
SynjardyEmpagliflozin/Metformin Hcl11$6,744
Combivent RespimatIpratropium/Albuterol Sulfate12$5,910

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$618$153,320120 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta$54$62,36996 claims
AbbVieLinzess$593$52,65979 claims
AstraZenecaFarxiga$60$50,73343 claims
Lilly USA, LLCMounjaro, Humulin 70-30$51$35,77450 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 292 adult health providers in South Carolina.

Other adult health in Mc Coll

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →